Blockbuster drugs are like rocket fuel for pharma stocks. When a hot new drug reaches blockbuster status with $1 billion in annual sales, two good things usually follow: Record revenue and record share prices. This was recently on display with pharma industry leader Gilead (Nasdaq: GILD). In 2012, Gilead released a promising drug called Sovaldi designed to treat Hepatitis C. Sovaldi was a big hit right away, reaching blockbuster status in its first year. That sent shares of Gilead soaring for the next three years. Take a look at the huge gains below. Today, I see this same… Read More
Blockbuster drugs are like rocket fuel for pharma stocks. When a hot new drug reaches blockbuster status with $1 billion in annual sales, two good things usually follow: Record revenue and record share prices. This was recently on display with pharma industry leader Gilead (Nasdaq: GILD). In 2012, Gilead released a promising drug called Sovaldi designed to treat Hepatitis C. Sovaldi was a big hit right away, reaching blockbuster status in its first year. That sent shares of Gilead soaring for the next three years. Take a look at the huge gains below. Today, I see this same pattern unfolding. One of the largest pharma companies in the high-growth cannabis sector is moving closer to the first ever cannabis blockbuster. Its promising new drug is in Phase 3 FDA testing, with a final decision expected by the end of 2017. I wrote about the promise of the medical cannabis industry last November. Here’s what I said at the time: This recent wave of legalization has given birth to the fastest-growing industry in North America. Market research firm Arcview is projecting North American legal cannabis industry sales to grow more than 200% in the next… Read More